---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-011988"
form_type: "8-K"
ticker: null
cik: "0001580063"
company_name: "BIORA THERAPEUTICS, INC."
filed_at: "2023-01-20T23:59:59+00:00"
generated_at: "2026-06-20T12:28:20.210885+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biora Therapeutics cures Nasdaq bid price deficiency; delisting hearing cancelled

## Summary
- Received Nasdaq compliance letter on Jan 19, 2023 confirming bid price deficiency cured.
- Company now in compliance with all applicable continued listing standards.
- Scheduled delisting hearing before Nasdaq Hearings Panel cancelled.
- Common stock (BIOR) will continue trading on The Nasdaq Global Market.

## SEC filing metadata
- accession: 0001193125-23-011988
- form_type: 8-K
- cik: 0001580063
- company_name: BIORA THERAPEUTICS, INC.
- filed_at: 2023-01-20T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580063/000119312523011988/0001193125-23-011988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580063/000119312523011988/d424427d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-011988
- JSON: https://secwatch.observer/filing/0001193125-23-011988.json
- Plain text: https://secwatch.observer/filing/0001193125-23-011988.txt

## Key facts
- Listing & Compliance Notices
  BIORA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding minimum bid price.
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: minimum bid price
  source text: January 19, 2023, Biora Therapeutics, Inc. (the “ Company ”) received a letter (the “ Compliance Letter ”) from Nasdaq notifying the Company that (i) the Company’s previously announced bid price deficiency had been cured and (ii) the Company was in compliance with all applicable continued listing standards. Accordingly, the Compliance Letter provided that the Company’s scheduled hearing had been cancelled. As previously disclosed, in December 2022, the Company received a determination from the Listing Qualifications Staff of The Nasdaq Stock Market LLC stating that, due to the Company’s contin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1580063/000119312523011988/0001193125-23-011988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.